MMHP
CRSP icon

Murphy Middleton Hinkle & Parker’s CRISPR Therapeutics CRSP Stock Holding History

Murphy Middleton Hinkle & Parker’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-906
Closed -$598K – 149
2025
Q4 		$598K Buy
+906
New +$54.3K 0.29% 87

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Murphy Middleton Hinkle & Parker's CRSP Position: Q1 2026 in Review

Murphy Middleton Hinkle & Parker sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 906 shares — an estimated $598K sold.

Murphy Middleton Hinkle & Parker first reported a position in CRSP in Q4 2025 and held it in 1 quarter. The position peaked at $598K in Q4 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Murphy Middleton Hinkle & Parker reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Murphy Middleton Hinkle & Parker sold 906 CRISPR Therapeutics shares in Q1 2026, an estimated $598K.
  • Murphy Middleton Hinkle & Parker first reported a position in CRISPR Therapeutics in Q4 2025 and held it in 1 quarter.
  • Murphy Middleton Hinkle & Parker's CRISPR Therapeutics position peaked at $598K in Q4 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Murphy Middleton Hinkle & Parker's 13F filing for Q1 2026, filed 15 Apr 2026.